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Influenza virus is one of the most pervasive pathogenic threats to the global public 
health on an annual basis. Each year, this RNA virus causes hundreds of thousands of 
deaths and billions of dollars in economic damage. The influenza vaccine is a key 
contributor in the fight against influenza infection and is available in several formulations, 
including the Live Attenuated Influenza Vaccine (LAIV). Although LAIV was sequenced 
nearly 20 years ago, the role of some of its genomic mutations have yet to be 
characterized. 
I believe the NS gene segment contributes to the attenuation phenotype of LAIV. 
To test this hypothesis, a panel of NS reassortant viruses in both the LAIV and 
A/Victoria/361/2011 backbones were generated. Additionally, a panel of recombinant 
viruses expressing a mutation at amino acid residue position 153 in the non-structural 
protein 1 (NS1) C-terminal domain were generated in both the LAIV and 
A/Victoria/361/2011 backbones. The NS reassortant viruses were generated, sequence 
verified, and characterized in MDCK and A549 cell culture systems. We show that a 
reassortant virus with LAIV NS in the A/Victoria/361/2011 backbone display faster growth 
kinetics in MDCK and A549 cell systems than its wild-type NS counterpart in the 
A/Victoria/361/2011 backbone. In MDCK cells, a reassortant virus with LAIV NS in the 
LAIV backbone displayed faster growth kinetics than a reassortant LAIV virus with wild-
type NS. However, there was no significant difference in A549 cells. These data indicate 
the NS gene segment of influenza has a role in viral replication. 
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Chapter 1 - Public Health Importance of Influenza 
 
1.1 Influenza in the Population 
 
 1.1.1 History 
 
 Influenza has been a persistent threat to global public health for hundreds, if not 
thousands of years. Some of the earliest reports of influenza infections can be traced back 
to the Hellenic Era in Greece during the 5th century BC 1. Historians suggest the first 
pandemic started in Asia in 1580 AD, spread to North Africa and Asia Minor into Europe 
2. In the span of six months, the pandemic had spread across the entirety of Europe and 
even to America. The ability for influenza to spread so readily is particularly impressive 
considering the lack of modern transportation like airplanes and motor vehicles. Nearly 10 
other pandemics have been reported since 1580, the most notorious being the 1918 
pandemic 1. 
 Although commonly referred to as the “Spanish Flu”, the name of the 1918 
pandemic is a bit of a misnomer. Some accounts attribute the source of the outbreak to 
Spain, others to America, and others still to China 1. Modeling by Taubenberger and 
Morens estimated that “one third of the world's population (or ≈500 million persons) were 
infected and had clinically apparent illnesses . . .total deaths were estimated at ≈50 million 
and were arguably as high as 100 million” 3. Hallmarks of the Spanish Flu included 
excessive morbidity in young adults (20-40 years old), a demographic that is historically 
quite resilient to influenza infections, and an increased susceptibility to secondary 
respiratory infections 4. The pandemic of 1918 perfectly illustrates the volatile and 
dangerous nature of influenza. Antigenically similar strains of an influenza virus can be 
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transmitted regionally on a year-to-year basis and have a mild impact on mortality and 
morbidity, however, antigenically novel pandemic viruses can arise with little warning and 
devastate public health on a global level. 
 
 1.1.2 Classification and Diversity 
 
 Influenza is an RNA virus that belongs to the family Orthomyxoviridae. Influenza 
A, B, and C are capable of infecting humans, however Influenza A and B are of major 
concern for seasonal infection.  Specific viruses are named in accordance with their 
influenza genera, location where strain was isolated, isolate number, and year isolated 5. 
For example, A/Victoria/361/1972 was isolate number 361 of an influenza A virus isolated 
in Victoria, Australia during 1972. Influenza A viruses can be further classified by the 
antigenic properties of their hemagglutinin  (HA) and neuraminidase (NA) surface 
glycoproteins 6. To date, 18 HA and 9 NA subtypes have been identified and 
characterized. Of these HA and NA subtypes, only H1, H2, H3 and N1, N2 are known to 
maintain continued transmission within human populations.   
 
 1.1.3 Mortality and Morbidity 
 
 Influenza has a tangible and significant impact on public health in the US and 
abroad. Molinari et al. examined domestic influenza infections for 2003 and modeled its 
burden on patient health and financial toll on the healthcare system. Influenza infects 
around 25 million Americans each year, which results in 31 million outpatient visits to 
healthcare facilities 7. Of these 31 million outpatient visits, up to 300,000 Americans are 
hospitalized each year as a result of influenza infection. Furthermore, around 30,000 
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patients will succumb to infection and die. It’s very important to note that many of these 
fatalities are not directly attributable to the influenza virus, but rather opportunistic 
secondary infections that present in the days and weeks following influenza infection.  
 The Molinari et al. study also examined the financial burden of influenza in the US. 
Roughly $87 billion was spent in 2003 to treat influenza and its sequelae. The vast majority 
of these costs (83%) were attributable to the healthcare of patients who would eventually 
succumb to infection. When examining financial burden in regards to age strata, adults 
over the age of 65 accounted for over 60% of the total economic burden. In America, 
influenza primarily affects the elderly and older adults. Only 15% of total influenza 
expenditures can be attributed to people between the ages of 0-49. 
 
 1.1.4 High Risk Populations 
 
 The very young ( < 5 years of age) are at elevated risk of influenza when compared 
to adult populations. It should be noted that of total pediatric influenza-related fatalities in 
the US between 2004 and 2015, healthy children under the age of 5 without pre-disposing 
medical conditions accounted for roughly 50% of case fatalities 8. Nearly half of these 
patients either died before being admitted to the hospital, had clinical illness for < 3 days 
(typical infection lasts 7 days), or had secondary bacterial infection 8. 
 On the other end of the age spectrum, the elderly ( > 65 years of age) also bear a 
disproportionate amount of morbidity and mortality to influenza infection. Approximately 
70-85% of seasonal influenza deaths and 55-70% of hospitalizations can be attributed to 
this age demographic 9.  Furthermore, when compared to the non-elderly, the elderly face 
a significantly greater risk of death (odds ratio = 2.95) in response to influenza infection 10. 
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There is also research to suggest that flu seasons in which H3N2 strains are predominant, 
the elderly face a much greater risk of influenza-related hospitalizations 11. 
 Exacerbation of pre-existing co-morbidities including Chronic Obstructive 
Pulmonary Disease (COPD), heart disease, and diabetes also significantly impacts a 
patient’s health outcomes. The presence of any co-morbidity was associated with an 
increased risk of death (odds ratio = 2.04) 10. These co-morbidities enhance the likelihood 
of hospitalization and the risk of developing pneumonia. When combined with pneumonia 
deaths, influenza was the #8 cause of death in the US in 201412. 
 Pregnant women are another group. During the 2009 pandemic H1N1 outbreak, 
when compared to their non-pregnant female counterparts, pregnant women exhibited 
higher rates of hospitalization, more admissions to the intensive care unit, and an 
increased likelihood of pre-term births and emergency cesarean sections 13. It’s believed 
that hormonal changes following conception disrupt inflammatory immune responses 
including natural killer cell activation, macrophages, and other Th1 response pathways 
that are crucial for combating diseases that are inflammatory, e.g. influenza 14. 
 The immunocompromised are at elevated risk of severe influenza infection 15. 
These patients typically have a chronic infection like HIV, have undergone organ 
transplant, or are undergoing treatment for certain types of cancer. Unlike healthy 
individuals in the general populations, they are unable to mount T cell responses, are 
taking immunosuppressive drugs, or are receiving bone marrow transplants, respectively. 
These factors make it easier for them to contract, and more difficult to clear influenza 
infection. While, they are still advised to receive their annual flu shot, Kunisaki and Janoff 
identified that this group has dampened humoral immune responses following vaccination 
and thus vaccination may have reduced efficacy in this patient population 15.  
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 The data presented thus far represents high-risk groups in developed nations, 
however, influenza also has a huge impact within the developing world. Nair et al. 
conducted a meta-analysis of 43 different studies that examined the mortality and 
morbidity of children within developing settings around the world. In 2008 alone, they 
estimated there were 90 million influenza infections in children under the age of 5, one 
third of which resulted in an influenza-related acute lower respiratory infection 16. Of the 
roughly 30 million children who contracted a secondary infection, around 100,000 children 
died. The study found a 15-fold difference in case fatality ratio between developed and 
developing settings. Much of this can be attributed to a lack of resources and infrastructure 
needed to provide basic healthcare to patients. In stark contrast to developed countries 
that see the elderly as bearing the brunt of influenza morbidity and mortality, the very 
young are the most impacted by influenza infection in developing nations. 
 
1.2. The Viral Lifecycle 
 
 1.2.1 Genome Structure and Organization 
 
 Influenza has a negative sense, single-stranded RNA genome consisting of 8 
unique gene segments. These gene segments are organized in order of decreasing gene 







1.2.2 Virus Infection and Assembly 
 
 Mature influenza A and B virions can be either spherical or filamentous in shape 
and recognize host epithelial cells via sialic acid residues on their surface 5. These sialic 
acid residues will either be in an α-2,3 or α-2,6- linkage conformation. HAs have different 
preferences for sialic acid linkage conformation, which help define host range and 
restriction. In the avian gut epithelium, α-2,3 linkages predominate, while the respiratory 
epithelium of humans varies based on location: the upper respiratory tract, the site of 
primary influenza infection, has mostly α-2,6 linkages, but α-2,3 linkages are more 
common in the lower lung 17,18. Like humans, swine posses both sialic acid receptor 
linkages. Since HA is the primary glycoprotein responsible for host cell recognition, 
neutralizing antibodies are often directed to HA-specific epitopes. This places a selective 
 Segment Approx. Length (base pairs)  Protein Encoded and Function 
1 PB2 2300 PB2- RNA Polymerase subunit 
2 PB1 2300 PB1 - RNA Polymerase subunit 
3 PA 2200 PA - RNA Polymerase subunit 
4 HA 1750 HA - binding and membrane fusion 
5 NP 1550 NP -  structural nucleoprotein 
6 NA 1450 NA - possesses a viral receptor destroying function necessary for vial release 
7 M 1000 M1 and M2 - encodes matrix proteins 
8 NS 875 
NS1 - antagonization of host immune 
responses 
NEP - viral RNP export from the nucleus 




1.2.2 Virus Infection and Assembly 
 
 Mature influenza A and B virions can be either spherical or filamentous in shape 
and recognize host epithelial cells via sialic acid residues on their surface 5. These sialic 
acid residues will either be in an "-2,3 or "-2,6- linkage conformation. HAs have different 
preferences for sialic acid linkage conformation, which help define host range and 
restriction. In the avian gut epithelium, "-2,3 linkages predominate, while the respiratory 
epithelium of humans varies based on location: the upper respiratory tract, the site of 
primary influenza infection, has mostly "-2,6 linkages, but "-2,3 linkages are more 
common in the lower lung 17,18. Like humans, swine posses both sialic acid receptor 
linkages. Since HA is the primary glycoprotein responsible for host cell recognition, 
neutralizing antibodies are often directed to HA-specific epitopes. This places a selective 
 Segment Approx. Length (base pairs)  Protein Encoded and Function 
1 PB2 2300 PB2- RNA Polymerase subunit 
2 PB1 2300 PB1 - RNA Polymerase subunit 
3 PA 2200 PA - RNA Polymerase subunit 
4 HA 1750 HA - binding and membrane fusion 
5 NP 1550 NP -  structural nucleoprotein 
6 NA 1450 NA - possesses a viral receptor destroying function necessary for vial release 
7 M 1000 M1 and M2 - encodes matrix proteins 
8 NS 875 
NS1 - antagonization of host immune 
responses 
NEP - viral RNP export from the nucleus 
Table 1. The Eight Gene Segments of the Influenza Virus 
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pressure on the virus to develop slight mutations in HA such that the host must generate 
new memory cells directed against the drift HA. This subtle process of mutation is termed 
antigenic drift. 
 Following HA binding of sialic acid, the virion is endocytosed into the host cell. 
Acidification of the endosome triggers a conformational change in HA that merges the viral 
envelope with the endocytic membrane, forming a pore 19. The influenza M2 protein then 
forms an ion channel for H+ ions to be pumped into the viral particle. The further 
acidification denatures protein-protein interactions and allows freed viral RNPs to be 
exported into the host cytosol. 
 Once in the cytosol, nuclear localization signals on the viral RNPs communicate 
their transport into the host nucleus. One of these RNPs, the RNA-dependent RNA 
Polymerase, synthesizes mRNA templates for viral protein synthesis and a complimentary 
negative sense genome to be packaged into immature virions 20. For proper maturation 
and export out of the nucleus, the PB1 subunit on the RNA Polymerase complex 
“snatches” 5’-guanosine caps from host pre-mRNA transcripts 21. This has a dual effect to 
shut down host mRNA translation while allowing for maturation of viral mRNA. The poly-
A tail of viral mRNAs is formed by encoding a series of 5-7 uracil residues on the negative 
sense script, which will then be transcribed into adenosine residues 22. Once the 5’-end 
has been capped and 3’-tail polyadenylated, viral mRNAs are transported out of the 
nucleus using host mRNA machinery; M1 and NEP mediates this process by interacting 
with viral RNA and bringing them into contact with the RNP complex 20. The viral genome 
assembles and is packaged into virions at the cellular membrane. Influenza virions bud 
from the cell membrane and the HA glycoprotein spikes continue to bind sialic acid 
residues on the cell surface. Viral release occurs when the NA protein utilizes its enzymatic 
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activity to cleave the sialic acid residue and release the influenza virion to infect other cells 
23. 
 1.2.3 Symptoms and Transmission 
 
 Although pandemics are rare in occurrence, influenza is transmitted from individual 
to individual year-round across the globe. Of the three types of flu, only Types A and B 
contribute to seasonal epidemics24. The virus is spread through aerosolized droplets that 
are released as part of coughing and sneezing. These droplets contain infectious virions 
that infect nearby individuals either through inhalation or direct contact. Infection occurs in 
the epithelial cells of the upper respiratory tract of a host, and clinical symptoms can 
manifest as soon as 24 hours post infection with the appearance of a fever (38oC - 40oC) 
25.  
 Symptoms are commonly characterized by malaise, body aches, runny nose, dry 
cough, excessive sputum production, and other generalized respiratory symptoms (WHO, 
2017). In healthy individuals with few pre-existing co-morbidities, symptoms typically 
resolve in one or two weeks26. However, those with chronic conditions are at greatest risk 
of fatal influenza infection, and may experience sequelae such as pneumonia that can 
complicate and prolong recovery12 
  There is a seasonality to influenza transmission (Figures 1 and 2). Generally 
speaking, the Northern Hemisphere experiences their peak transmission during the winter 
months - November through March. The Southern Hemisphere experiences their peak 
transmission during the late spring and summer months - April through August. The 
seasonality of influenza transmission in the tropics is much less defined, and outbreaks 


















Unfortunately for epidemiologists and public health professionals, there is no 
discrete, singular reason why influenza infections peak during the winter months. One 
theory posits that serum levels of Vitamin D drop during this time as people are less likely 
to be outside27. Vitamin D has been connected to promoting mucosal and CD4+ T cell 
responses, so influenza may be able to infect hosts more readily as Vitamin D levels drop 
28. Some believe the seasonality of flu is related to social and behavioral factors including 
crowding which helps transmission by exposing more people to the aerosolized droplets 
of an infected individual 29. A new theory suggests that the innate immune response is 
dampened by a drop in ambient temperature. Foxman et al. demonstrated that rhinovirus 
is able to infect humans more readily at 33o C due to diminished response by Type I 
interferons 30. It would be particularly interesting to see if lowered ambient temperatures 
Figure 2. Positive Influenza Infection Tests in the Southern Hemisphere during 2016-2017. 
WHO, 2017 
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enable influenza infection, or if viral proteins are better at inhibiting host immune 
responses at lower temperatures. A leading theory believes that a combination of 
temperature and humidity is the driving force in influenza seasonality. Guinea pigs held in 
cages at 5oC and low humidity were much more prone to influenza infection than those 
held at 30oC and normal/high humidity conditions 31. Lowen and Steel attribute the higher 
infection rates to an increase in virion stability while aerosolized, however this is also highly 
dependent on the pH and salt balance of the droplets. 
 The underlying seasonality of influenza infection is far too complex to attribute to 
a single environmental or host immune factor. It’s much more likely that a series of factors 
work in sync to increase infection rates during particular times of the year. 
 
1.3 Influenza Vaccines 
 
 1.3.1 Vaccine Development 
 
 The manufacture of the influenza vaccine is a yearlong process that is coordinated 
through 80 different countries and requires a large amount of collaboration to ensure a 
viable vaccine is produced in sufficient quantity for distribution. Throughout the year, 
sentinel physicians send nasopharyngeal swabs from suspected influenza cases to WHO 
centers to sequence the HA and NA surface glycoproteins from the patients to monitor 
mutations that may change the antigenicity of either protein. Novel strains are sent to one 
of four influenza research centers for further molecular and genetic analyses 32. The 
strains included in the annual influenza vaccine reflect the isolated strains obtained from 
yearlong surveillance. For countries in the Northern Hemisphere, circulating flu strains are 
reviewed in February to determine their potential for circulation during the next flu season. 
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The antigenic drift of existing vaccine strains is also evaluated in case a strain update 
needs to be made. Once the vaccine composition has been decided, vaccine companies 
have around 8 months to produce and release vaccines to health care providers 32.   
 In recent years, seasonal vaccines have included one H1N1, H3N2, and Influenza 
B strain which reflect the predominant circulating strains. Reassortant viruses are 
generated by growing the selected H1N1 and H3N2 strains in embryonated hen’s eggs 
alongside an A/PR8/1934 strain which grows to high titer in eggs 33. The surface proteins 
of progeny viruses are antigenically very similar to their wild type circulating precursors, 
but are still tested for their absence of genes coding for A/PR8/1934 surface glycoproteins. 
As part of the serial passage process, progeny viruses also develop mutations in order to 
propagate within eggs - these mutations must be tested to ensure they have not changed 
the antigenicity of the virus. There are no “master strains” for reassortant Influenza B 
viruses, so field isolates must be used.  
 The surface antigens of candidate strains are tested for their homology to the 
reference viruses and then sent to vaccine manufacturers to evaluate their potential for 
mass production. Strains that meet both of these criteria are selected for the annual 
vaccine. Vaccine strains are grown in the allantoic cavity of embryonated eggs, harvested, 
and inactivated by formalin or another similar agent. Next, the strains are partially purified 
by ultra-centrifugation and mild detergent disruption. After these steps, manufacturers 
must prove the purified strains have had no changes to the HA and NA genes. Finally, the 
antigen concentration of the purified viruses is quantified by an immune-diffusion assay. 
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In European countries, finalized vaccine candidates must undergo clinical studies to prove 
their safety and immunogenicity - this is not required in the United States. 
 1.3.2 Vaccine Composition 
 
 There are two formulations for the annual vaccine. The most common is the 
injectable formulation that contains formalin-inactivated virions34. These virions have no 
ability to replicate within the host, but are capable of inducing a memory response by the 
immune system. The inactivated vaccine has greatest efficacy in patients above the age 
of 6 35. The increased efficacy in older children is most likely attributable to past infection 
with influenza virus.  
 The other formulation is a live attenuated influenza vaccine (LAIV) that is 
administered through a nasal spray into the nasopharyngeal region of the upper 
respiratory tract36. As the name implies, this is a live virus that can replicate within the 
host, but does not cause disease. This area of the body maintains a temperature around 
32oC which permits localized viral growth, but prevents systemic infection into the lower 
airways which maintain a temperature around 37oC. LAIV is of note because its 
administration has been connected to a broad and systemic IgA mucosal response to not 
Figure 3. Flu Vaccine Development Timeline for the Northern Hemisphere. USA Today, 2009 
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only the vaccine strains, but also strains that have undergone genetic drift/shift 37. The live 
virus formulation is currently only recommended for people between the ages of 2-49 and 
those who are not immunocompromised. 
 The inactivated and live attenuated formulations can be either trivalent or 
quadrivalent. The trivalent vaccines have two influenza A strains and one influenza B 
strain. The trivalent vaccine for the 2016-2017 season consisted of A/California/7/2009 
(H1N1) pdm09-like, A/Hong Kong/4801/2014 (H3N2), and B/Brisbane/60/200834. The 
quadrivalent vaccines are identical to their trivalent counterparts except they contain a 
second influenza B strain. 
 Growing vaccine strains in eggs has the disadvantages of scalability, potential for 
undesirable mutations that decrease antigenicity of vaccine strains, contamination, and 
constraints on egg availability, which has led to alternative means of production being 
investigated. Cell lines may minimize some of these disadvantages, such as reducing the 
risk of accidental mutations during the production process 38. Furthermore, cells have the 
advantage of being cryopreserved, stored, and scaled up if the need arises. Grown in 
Madin-Darby Canine Kidney cells, FLUCELVAX® is the first cell-based vaccine to be 
approved by the FDA and was first offered during the 2016-2017 flu season39. Clinical 
studies indicated this vaccine induced immunogenicity to circulating influenza strains while 
also demonstrating similar side effects to egg-derived vaccines 40.  
 Baculovirus expression vectors also represent a step forward in influenza vaccine 
development. In this system, recombinant baculoviruses are engineered to encode a 
cDNA for a foreign protein of interest 41. These viruses then infect insect or plant cells, 
producing the mRNA transcripts which can then be harvested and translated to the desired 
protein. Flublok® is a novel vaccine though which recombinant influenza hemagglutinin is 
produced, harvested, and purified into a vaccine formulation through these baculovirus 
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vectors. There are numerous advantages to baculovirus vectors when compared to eggs 
for vaccine production. One of the greatest benefits of this system is its safety. 
Baculoviruses are present on nearly every type of leafy green vegetable (and are ingested 
on a daily basis by humans) and are only known to infect moths and butterflies. 
Furthermore, much like cell culture systems, baculovirus systems are very scalable and 
take less time to clone, express, and manufacture the recombinant HA 42. 
 
1.4 Non-Structural Protein 1 
 
 1.4.1 Protein Overview 
 
 The NS gene of influenza viruses encodes two separate proteins, non-structural 
protein 1 (NS1) and nuclear export protein (NEP). Both of these proteins are produced 
during an infection, but are not packaged into progeny virions. The NS1 protein is a 
multifunctional protein, however its overall role in antagonizing innate immune responses 
can be connected to one of its two functional domains. The first is the N-terminal domain, 
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also known as the RNA-binding domain, and then the C-terminal domain, also known as 
the effector domain 43.  
 
 1.4.2 Structure and Function of the N-terminal Domain 
 
 The N-terminal domain is roughly defined as amino acids 1-73 of the NS1 protein. 
As mentioned previously, the N-terminal domain of NS1 is responsible for directly binding 
host RNA and preventing its transcription into proteins. The N-terminal domain forms a 
homodimer in solution that consists of three α-helical domains which constitute the 
majority of secondary structure for this region of the protein. This dimerization is crucial 
for RNA binding. The α-helices of the homodimer form a unique chain fold that binds RNA 
between the 2 and 2’ chains 43. Research has determined that within the second α-helix, 
R38 and K41 are the two crucial amino acids needed for RNA-binding 44 
 The NS1 N-terminal domain is well-known for inhibiting the 2’-5’ oligoadenylate 
synthetase (OAS)/RNAse L pathway. The OAS/RNAse L pathway is activated by IL-1β, a 
Figure. 4. Structure of the NS1 Protein and Cellular Targets of Immune Inhibition. Hale et al., 2005 
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key cytokine in initiating a wide array of innate immune responses, and is known to induce 
an antiviral response by recognizing and degrading foreign dsRNA 45. It was originally 
thought that NS1 inhibited production of IL-1β which would block OAS/RNAse L. However, 
work conducted by Min and Krug found that NS1 functions not to prevent the transcription 
of IL-1β, but rather to directly bind viral dsRNA and sequester it from the OAS recognition 
complex and thus prevent its degradation via RNAse L 46. Furthermore, Min and Krug 
found that an R38A mutation in the N-terminal domain effectively abolished NS1 inhibition 
of the OAS/RNAse L pathway. This discovery implicates point mutations as key mediator 
of NS1 antagonism of the innate immune system. 
 The N-terminal domain has also been proven to directly inhibit the production of 
key innate cytokines including IL-1β and IL-18. Stasakova et al. utilized A/Puerto 
Rico/1934 viruses with nucleotide base deletions in the C-terminal of the NS1 protein. The 
levels of IL-1β and IL-18 in the truncated NS1 mutant viruses were found to be similar to 
that of the full-length A/Puerto Rico virus 47. Furthermore, mutant viruses expressing an 
impaired N-terminal domain resulted in IL-1β levels that were 10-50 times higher, and IL-
18 levels that were five times higher than the full length virus. These data implicate the N-
terminal domain of NS1 in IL-1β and IL-18 inhibition. 
 
 1.4.3 Structure and Function of the Linker Region 
 
 There is a short linker region of roughly 11 amino acids that separates the N-
terminal and C-terminal domains. The length of the linker region is strain dependent and 
is believed to give NS1 a certain degree of flexibility with the C-terminal rearranging itself 
around a stationary N-terminus 48. This will influence the three-dimensional structure of 
the protein and potentially alter its interaction with other cellular factors. Truncated linker 
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regions have been connected to an increase in virulence in some H5N1 viruses, 
suggesting its potential importance in modulating NS1 function 49. 
 
 1.4.4 Structure and Function of the C-terminal Domain 
 
 The C-terminal domain of NS1 is characterized as extending from amino acids 85 
to the end of the protein; the exact length of the C-terminus is strain-dependent. Although 
the N-terminus remains dimeric throughout the course of infection, the C-terminus is 
capable of forming dimers or remaining monomeric 48. Since both functional domains of 
NS1 act as dimers, researchers now believe the protein acts as a dimer in vivo 50. 
However, NS1 can cycle between monomeric and dimeric conformations to determine 
which is most beneficial at that point of the infection. For example, the protein may be 
monomeric during early infection when the protein concentration is low, but may then cycle 
to an open dimer during later stages when the protein concentration has increased and 
can bind host factors like CPSF30. These structures can be further influenced in a strain-
dependent manner. The tertiary structure of the C-terminal domain, as well as the N-
terminal domain is fairly conserved across influenza strains. However, the effector domain 
is known to display polymorphisms that influence its interaction with host mRNA 
transcripts and cellular factors. Carrillo et al. determined there are three main classes of 
NS1 effector domain orientation: open, semi-open, and closed 48. Furthermore, there is 
evidence to suggest that these orientations are influenced by linker region length and 
residue composition. This flexibility may allow for varying conformations in quaternary 
structure that would influence NS1’s interactions with host factors and result in the 
protein’s known multi-functionality 51.  
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 The C-terminal domain of NS1 is multifunctional and works to inhibit host cell 
innate immune responses to various degrees. 
 One of the most studied targets of NS1’s C-terminal domain is cleavage specific 
polyadenylation factor (CPSF30). CPSF30 is responsible for the maturation of host pre-
mRNA by cleaving the 3’-end of the transcript and then polyadenylating the end of the 
cleavage site 52. This process is critical for proper development of host mRNA such that it 
can be exported from the nucleus. NS1 functions to bind and sequester CPSF30 so it 
cannot complete this function. The result is a bottleneck on the export of host mRNA, most 
notably mRNA encoding Type I interferons. As the host mRNA accumulates, the viral 
replication complex binds host transcripts via the PB2 subunit, cleaves the transcripts via 
the PA subunit, and finally prepares viral mRNA synthesis with the PB1 subunit 53. It’s 
necessary to note that these viral RNA transcripts can be transcribed independently of 
host machinery and are thus selectively omitted from this block on transcription.  
 Discrete amino acids are crucial for the bioactivity of the NS1 effector domain. 
Work conducted by Twu et al. demonstrated that viruses with mutations at residues 144 
and/or 186 in their NS1 C-terminus had 40 times more IFN-β than their wild type 
counterpart 54. These researchers also implicated the a.a. 144-186 region as the binding 
site for the F2F3 zinc finger on CPSF30 54. These findings were built upon by Das et al. 
who demonstrated that amino acids F103 and M106 were crucial to maintain the stability 
of the NS1-CPSF30 complex 55. These residues were highly conserved across > 99% of 
Influenza A strains and present an interesting target for anti-viral drug design in the future 
These data further reinforce the belief that point mutations in the NS1 protein can 
drastically influence the attenuation of influenza A viruses. It is also necessary to note that 
circulating seasonal influenza viruses show a strong capability to bind CPSF30, while egg 
adapted strains lack this trait 56. Further work needs to be conducted to determine if egg 
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adapted strains attribute their adaptation specifically to inability to bind and inactivate 
CPSF30. 
 PABPII works in conjunction with the CPSF30 complex. CPSF30 cleaves the 3’-
end of the pre-mRNA transcripts while PABPII ligates the complex following cleavage. 
Unsurprisingly, NS1 targets PABPII in addition to CPSF30. NS1 inhibition of PABPII is 
also believed to affect export of mRNAs. The PABPII complex is known to shuttle between 
the nucleus and cytoplasm and it has been hypothesized it may play a role in both the 
maturation and delivery of host mRNAs. Li et al. demonstrated that cells transfected with 
NS1 have sequestered and relocalized PABPII in the nucleus where it cannot interact with 
host mRNA 57. Furthermore, the NS1 C-terminal domain appears to have non-overlapping 
regions that bind CPSF30 and PABPII - this means one protein can effectively bind and 
neutralize two host transcription factors. CPSF30 and PABPII also bind each other in vitro 
and form a complex. These data suggest that although CPSF30 may be able to bind host 
pre-mRNAs during an influenza infection, the conjoined binding with PABPII on the NS1 
protein may still inhibit the proper maturation of host transcripts. Once again, point 
mutations in the aa 223-237 were implicated in NS1 binding on PABPII. 
 Protein kinase R is an intracellular sensor for dsRNA and serves as an important 
part of the innate immune system. Once activated by dsRNA, PKR phosphorylates the 
eIF2 translation factor which in turn halts host protein synthesis for both normal host 
function and viral invaders 58. Influenza counteracts this in two ways. The first is inhibition 
of p58IPK, a factor that is required to activate PKR 59. Secondly and more important for 
this research, is inhibition of PKR by NS1. NS1 binds amino acids 123-127 in the C-
terminal domain and is believed to trigger a conformational change in PKR 60,61. This 
conformational change prevents PKR from binding viral dsRNA and thus inhibiting its 
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translation. Once more, point mutations are implicated in maintenance of pro-viral 
functions in the host. 
 
1.5 The Live Attenuated Influenza Virus 
 
 1.5.1 Overview and Description 
 
 The live attenuated influenza virus (LAIV) was developed concurrently in the US 
and USSR during the 1960s. The A/Ann Arbor/6/60 (US) and A/Leningrad/134/47/57 
(USSR) wild type strains are both H2N2 viruses that were serially passaged at 
progressively lower temperatures in embryonated hens eggs 62. As part of the serial 
passaging process, the wild type strains developed a set of mutations in its genome that 
allowed for its propagation under these conditions. The result was an antigenically distinct 
cold adapted (ca) progeny strain of the clinically isolated wt A/Ann Arbor/6/60. Genomic 
analyses have connected these mutations to three main phenotypes of LAIV that 
contribute to its attenuation. 
 
1) Cold Adaptation - LAIV can propagate at 25oC. This is considerably lower than the 
core human body temperature of 37oC. 
 
2) Temperature Sensitivity - LAIV has diminished replication efficiency at 37oC. LAIV 
is delivered into the nasopharyngeal tract via intranasal administration where the 
virus can replicate at 32oC. Although the upper airways permit a small, localized 
infection, the temperature sensitivity of the virus prevents it from spreading into the 
lower airways (temp. ≈ 37oC) which is associated with a more severe infection. 
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Instead, the virus remains localized to the upper airways where it can be controlled 
by the immune response. 
 
3) Attenuation - Ferrets represent an animal model of influenza infection 63. It has 
been shown that LAIV infection in these mammals limits influenza infection to the 
upper airways, but still induces a protective antibody response 64. Furthermore, 
histological analyses of ferrets infected with LAIV demonstrated fewer lesions than 
those who were inoculated with the wild-type strains. 
 
 1.5.2 LAIV Formulation 
 
 In terms of an annual influenza vaccine, reverse genetics are used to create an 
LAIV through a 6:2 reassortment with the circulating wt virus of concern. The allantoic 
cavity of an embryonated hen’s egg is infected with a cold adapted influenza strain like 
A/Ann Arbor/6/60 and the circulating strain of choice. In the egg, the six internal gene 
segments (PB2, PB1, PA, NP, M, NS) of the cold adapted strain reassort with the HA and 
NA from the circulating strain 65. The resulting virus inherits the temperature sensitivity and 
attenuation of the cold adapted virus, but contains the external genes of the circulating 











1.5.3 NS1 Mutations in LAIV 
 
 It’s clear that point mutations are responsible for the attenuation and temperature 
restriction of LAIV. Most of the mutations occur in the genes encoding viral polymerases, 
however a few have been discovered elsewhere in the genome, notably in the NS gene.  
 Work conducted by Cox et al. mapped one mutation in the coding region of the NS 
gene segment. Occurring at amino acid 153, the mutation from an alanine (wt) to a 
threonine (LAIV) was the only difference in the coding region of the NS gene of cold 
adapted A/Ann Arbor/6/60 when compared to the wt 66. When examined in the same 
context as some of the other gene segments, it’s reasonable to infer that the mutation at 
aa 153 of NS might have a role in LAIV attenuation.  
Figure 5. Formulation of LAIV. Modified from NIAID. 
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1.5.4 Previous Data 
 
 Work conducted by Fenstermacher and Forero examined the growth kinetics of 
HA/NA-antigenically matched LAIV and wt A/Victoria/361/2011 in cultures of human nasal 
epithelial cells (hNECs) at 33oC. They found that over a seven day period, infectious 
particle production as well as growth rate in LAIV was less than its wt counterpart 67.  
 In addition to altered growth kinetics, LAIV differentially induces the host innate 
immune response when compared to a wt virus. When hNEC cells were infected at a high 







Segment Coding Changes Mutation Effect 
PB2 1 N265S Attenuation, Temp. Sensitivity 
PB1 4 K391E, E457D, E581G, A661T Attenuation, Temp. Sensitivity 
PA 2 K613E, L715P Cold Adaptation, Attenuation 
NP 2 T23N, A34G ? 
M 1 A86S Attenuation 
NS 1 A153T ? 





















At 24 hours post infection, LAIV induces over twice the amount of unique genes 
when compared to the wt. Furthermore, at 36 hours post infection, LAIV induces six times 
Figure 7. LAIV Differentially Induces the Immune Response. Forero and Fenstermacher et al., 
ahead of print. 
Figure 6. LAIV Demonstrates Altered Growth Kinetics when Compared to wt 
A/Victoria/361/2011. Forero and Fenstermacher et al., ahead of print. 
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the amount of genes distinct from wt. These data indicate LAIV and circulating wt viruses 
differ in both replication and induction of the immune response, however the mechanistic 
basis of these differences remains to be fully understood. 
 Previous work indicates that discrete amino acids are crucial for NS1’s bioactivity. 
Recent work conducted by Nogales et al. demonstrated that D189N and V194I mutations 
in clinical isolates contributed to viral attenuation and temperature sensitivity, particularly 
at aa 194 (Nogales et al., 2016). Furthermore, DeDiego et al. has shown that H3N2 viruses 
bearing an I64T mutation are particularly susceptible to IFN-based responses 68. 
 In the context of these data, we believe the aa 153 mutation in the NS segment 
may contribute to the attenuation of LAIV by participating in restricting viral growth and/or 
differentially inducing immune genes distinct from wt influenza infection. 
 
Chapter 2 - NS Segment Reassortant Viruses between 





 2.1.1 Influenza and Gene Reassortment 
 
 Reassortment of the influenza genome is a normal part of the virus lifecycle in 
which entire gene segments are replaced by those of another influenza strain. This often 
occurs in an intermediary species, swine for example, where avian and human influenza 
viruses can co-mingle within the same pig 69. For example, a human influenza can some 
of its gene segments with that of an avian strain. The resulting reassorted virus has traits 
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of both its parental viruses which can have a profound impact on virulence within a naive 
host.  
 This process of reassortment is commonly known as genetic shift when it involves 
the HA gene segment and is a hallmark of influenza diversity and adaptation. Many 
pandemic strains have formed as a result of gene reassortment including the 1918 H1N1, 
1957 H2N2, 1968 H3N2, and most recently 2009 H1N1 outbreak. A closer look at the 
1918 pandemic strain shows the acquisition of an avian HA gene which drastically 













2.1.2 Reassortant Viruses in the Laboratory 
 
 In the laboratory, we are able to manually induce gene reassortment to create new 
influenza viruses. In fact, this is done on an annual basis with LAIV which contains the six 
internal cold adapted genes from the attenuated virus, as well as the two external genes 
Figure 8. Hypothetical Reassortment of Influenza within a Swine Host. Stevens et al., 2006. 
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from the circulating virus subtypes. When a single segment is substituted for another, the 
resulting virus is referred to as a “7:1 virus” to represent the seven original segments and 
the one transplant segment. These reassortant viruses are useful in determining the 
influence of a particular segment on viral phenotype. For example, the aforementioned 
work conducted by Pappas et al. was done with reassorted H1N1 viruses to elucidate that 
HA was the crucial segment conferring enhanced virulence in the 1918 pandemic strain. 
For the purposes of this project, we intend to do NS gene swaps between LAIV and wt 
A/Victoria/361/2011.  
 
 Lineage of Segments 1-7 Lineage of NS Segment Abbreviation 
1 A/Victoria/361/2011 A/Victoria/361/2011 WT/WT 
2 A/Victoria/361/2011 LAIV WT/LAIV 
3 LAIV LAIV LAIV/LAIV 
4 LAIV A/Victoria/361/2011 LAIV/WT 
 
Table 3. 7:1 Virus Panel 
Figure 9. Representation of 7:1 NS Gene Swaps between wt A/Victoria/361/2011 and LAIV 
 29 
Since the NS segment encodes two proteins, NS1 and NEP, sequence alignments 
of wild type A/Victoria/361/2011 and LAIV NS1 and NEP were performed in order to 
examine amino acid differences. There are 28 discrete amino acid differences between 
the wild type and LAIV NS1 proteins. In regards to NEP, there are 7 discrete amino acid 
differences.  When used in our NS reassortant virus system, this variation in amino acids 
between the protein sequences might shed light on LAIV attenuation. 
 
2.2 Materials and Methods 
 
 2.2.1 Cell Lines 
 
 Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
ug/mL streptomycin and 2mM L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 
dilution every 3-4 days. 
Figure 10. Sequence Alignment of wild type A/Victoria/361/2011 and LAIV NS1 
Figure 11. Sequence Alignment of wild type A/Victoria/361/2011 and LAIV NEP 
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 Transformed human embryonic kidney 293 cells (293T) were maintained in DMEM 
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 ug/mL streptomycin and 2mM 
L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 dilution every 3-4 days. 
 Adenocarcinomic human alveolar basal cells (A549) were maintained in DMEM 
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and100 ug/mL streptomycin at 
37oC with 5% CO2 and passaged at a 1:10 dilution every 3-4 days. 
 
 2.2.2. Recombinant Viruses 
 
 A 12 plasmid recombinant virus rescue system was utilized to generate the panel 
of reassortant viruses (Neumann et al., 1999). 6-well plates were coated with poly-L-lysine 
and 293T cells were plated at 40-60% confluence 24 hours prior to transfection. For the 
reassortant viruses with the A/Victoria/361/2011 genome, 293T cells were transfected with 
A/Victoria/361/2011 pHH21 plasmids encoding the A/Vic PB2, PB1, PA, NP, NA, HA, M 
(0.5 μg each) and the LAIV NS segment (1.0 μg). For reassortant viruses with the LAIV 
genome, 293T cells were transfected with LAIV pHH21 plasmids encoding PB2, PB1, PA, 
NP, NA, HA, M (0.5 μg each) and the A/Vic segments HA, NA, and NS (1.0 μg). All pHH21 
plasmids were transfected with helper plasmids encoding the ORFs of the A/Udorn/72 
PB1, PB2, NP (1.0 ug each) and PA (0.2 uh) under the control of RNA polymerase II 
promoters which allows for expression of the viral proteins needed for RNA replication.  
 Transfection reagent TransIT-LT-1 (LT1) (Mirus) (20 μL/transfection) was mixed 
with OptiMEM medium (Gibco) (100 μL/transfection) and incubated at room temperature 
for 15 minutes. Plasmids were mixed at the aforementioned quantities, added to the 
LT1/OptiMEM mixture, and incubated at room temperature for another 15 minutes. DMEM 
was aspirated from 6-well plates containing 293T cells and replaced with 2 mL/well of 
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OptiMEM. The corresponding transfection mix was added dropwise to each well. The 
plates were incubated at 32oC with 5% CO2. 24 hours following transfection, 2.24 μL of 5 
μg/mL N-acetyl trypsin (NAT) (Sigma) was added to each well to bring the total 
concentration of NAT to 10 μg/mL. The cells were incubated at 32oC with 5% CO2 for 4 
hours and then each well overlaid with approx. 5*105 MDCK cells suspended in 100 μL 
OptiMEM. The plates were transferred to a 37oC incubator. Every 24 hours for approx. 
five days, 1 mL of supernatant was removed from the cells and replaced with 1 mL DMEM 
with 4 μg/mL NAT, 100 U/mL penicillin, 100 μg/mL streptomycin, 2mM L-glutamine, and 
0.5% bovine serum albumin (BSA) (Sigma) (IM+NAT). Transfection was discontinued 
when indications of comprehensive cytopathic effects were observed. 
 WT/WT, WT/LAIV, LAIV/LAIV, and LAIV/WT reassortant viruses were generated 
in accordance with this protocol. 
 
 2.2.3 TCID50 Assay 
 
 Fifty percent tissue culture infectious dose (TCID50) were utilized to determine viral 
titers. MDCK cells were plated to confluence in 96-well plates. Viral supernatants were 
diluted at concentrations from 10-1 to 10-8 in IM+NAT. 20 μL of each 10-fold dilution was 
added to six consecutive wells on a confluent 96-well plate containing MDCK cells. These 
plates were incubated at 32oC with 5% CO2 for 7 days. The cells were fixed with 4% 
formaldehyde and stained with naphthol blue-black overnight. Cytopathic effects (CPE) 
were scored visually and TCID50 was quantified using the Reed and Muench calculation. 
 
 2.2.4 Plaque Purification 
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 Recombinant influenza viruses generated following transfection must be purified 
from the transfection supernatant. 6-well plates were seeded with MDCK cells and seeded 
to confluence. 100 μL of transfection supernatant was serially diluted ten-fold from 10-1 to 
10-8 with IM+NAT. 6-well plates were aspirated and washed twice with PBS+. 250 μL of 
diluted virus (dilutions determined from TCID50 of transfection supernatant) was added to 
each well. The 6-well plates were incubated for one hour at 32oC for the LAIV/LAIV and 
LAIV/WT viruses and 37oC for the WT/WT and WT/LAIV viruses. During the incubation 
period, the plates were gently tapped every 15 minutes to evenly distribute virus. Following 
incubation, the inoculum was aspirated and replaced with ~ 4 mL of a mixture of 2% 
agarose, 2X Modified Eagle’s Medium (MEM), and 4 μg/mL NAT. Plates were incubated 
at 32oC for 72-120 hours. Clear, defined, and singular plaques were picked using a 1 mL 
serological pipette, placed into tubes containing 500 μL IM, and stored at -80oC. 
 
 2.2.5 Virus Infection to Generate Viral Stocks 
 
 MDCK cells were grown to confluence in T150 (150 cm2) flasks. 100 μL of the 
media containing the plaque plug was added to 5 mL IM+NAT. The media was aspirated 
from the T150 flasks and replaced by the virus and IM mixture. The flasks were incubated 
for one hour at 32oC for viruses with LAIV polymerase genes and 37oC for viruses with 
A/Victoria/361/2011 polymerase genes. During the incubation period, the plates were 
gently tapped every 15 minutes to evenly distribute virus. Following the one hour 
incubation, the inoculum was aspirated and replaced with 20 mL IM. The cells were 
monitored daily for CPE and the supernatants harvested after 30-40% of cells were dead 
or had detached from the flask. The infected cell supernatants were aliquoted into 200 μL 
volumes and stored at -70oC to establish a bank of viral seed stocks. The seed stocks 
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were sequenced to confirm a purified virus product and later infectious virus titers 
determined via TCID50 assay. Once viral sequencing was completed, working stocks were 
generated from the seed stocks (MOI = 0.001) in the manner described above. Working 
stocks were also titrated for infectious virus via TCID50 assay. 
 
 2.2.6 Low MOI Growth Curves 
 
 Growth curves were implemented to examine virus replication kinetics and peak 
viral titers mimicking natural infection. 24-well plates were seeded to confluence with either 
MDCK or A549 cells. Viruses were diluted to a multiplicity of infection (MOI) of 0.01 
infectious viral particles per cell in IM+NAT. The NAT was added at a 1:1000 dilution for 
MDCK cells and 1:5000 dilution for A549 cells. The media was aspirated from the 24-well 
plates and each well was washed twice with PBS+. 250 μL of virus was added to 
appropriately labeled wells and incubated for one hour at 32oC or 37oC. The viral inoculum 
was removed after the one hour incubation, the cells were washed twice with PBS+, and 
500 μL IM+NAT added to each well. The IM+NAT was removed, stored, and replaced with 
fresh media at 1, 12, 24, 36, 48, and subsequent 24 hour time points until the cells has 
comprehensive CPE. The infectious virus titers were determined via TCID50 assay. Virus 
particle production was graphed using Prism 7 software. 
  
2.2.7 High MOI Growth Curves 
 
 Growth curves were implemented to examine virus replication kinetics and peak 
viral titers. 24-well plates were seeded to confluence with A549 cells. Viruses were diluted 
to a multiplicity of infection (MOI) of 0.55 infectious viral particles per cell in IM+NAT. The 
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media was aspirated from the 24-well plates and each well was washed twice with PBS+. 
250 μL of virus was added to appropriately labeled wells and incubated for one hour at 
32oC and 37oC. The viral inoculum was removed after the one hour incubation, the cells 
were washed three times with PBS+, and 500 μL  IM+NAT added to each well. The 
IM+NAT was removed, stored, and replaced with fresh media at 1, 12, 18, 24, 36, 48, and 
subsequent 24 hour time points until the cells had comprehensive CPE. The collected 
supernatant was titered via TCID50 assay. Virus particle production was graphed using 




 2.3.1 Rescue of NS Reassortant Viruses 
 
  NS reassortant viruses were successfully rescued. All eight gene segments were 
sequenced to ensure there were no incidental mutations that occurred during the 
transfection process. 
 
 2.3.2 Replication of NS Reassortant Viruses at 32oC in MDCK Cells 
 
 To characterize replication kinetics and peak viral titers of NS reassortant viruses, 
a multi-step growth curve was performed on MDCK cells at 32oC. This temperature was 
selected in order to mimic the temperature of the upper respiratory tract. When matched 
for genetic backbone, the LAIV/LAIV virus had significantly faster replication kinetics than 
the LAIV/WT virus, however they both reached the same peak titer at 72 hours post 
infection (Fig. 12). The WT/LAIV virus also had significantly faster replication kinetics than 
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the WT/WT virus, however both reached roughly the same peak titer at 72 hours post 
infection (Fig. 13). 
 
 



















Figure 12. Effect of NS Gene Swap in the LAIV backbone at 32oC in MDCK Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 





2.3.3 Replication of NS Reassortant Viruses at 37oC in MDCK Cells 
 
 A multistep growth curve was also performed at 37oC to mimic an infection of the 
lower respiratory tract, which is also representative of core body temperature. Once again, 
the LAIV/LAIV virus had significantly faster replication kinetics than LAIV/WT, but both 
viruses achieved roughly the same peak titer at 48 hours post infection (Fig. 14). 
Additionally, the WT/LAIV virus had significantly faster replication kinetics than the WT/WT 
virus, however both strains reached roughly the same peak titer at 48 hours post infection 
(Fig. 15). 



















Figure 13. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 32oC in MDCK 
Cells. A multistep growth curve was performed on MDCK cells with the indicated viruses. 
Statistical differences were determined by MANOVA followed by Bonferroni post-test. *=P < 



































Figure 14. Effect of NS Gene Swap in the LAIV backbone at 37oC in MDCK Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 
***=P<0.001. L.O.D=limit of detection=2.37. 
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2.3.4 Replication of NS Reassortant Viruses at 32oC in A549 Cells 
 
 A549 cells were infected to further evaluate viral growth kinetics for the NS 
reassortant viruses. Originating from adenocarcinomic alveolar basal epithelial cells, 
A549s present a more humanized model for influenza infection than MDCK cells. The 
A549 cells were infected at an MOI = 0.55. 
 A multistep growth curve was performed at 32oC. For the viruses in the LAIV 
backbone, the LAIV/LAIV and LAIV/WT viruses show no significant difference in 
replication kinetics – both viruses reached roughly the same peak titer at a similar rate 
(Fig. 16). For the viruses in the A/Victoria/361/2011 backbone, the WT/LAIV virus reached 
a peak titer nearly 100-fold greater than its WT/WT counterpart. Furthermore, the WT/LAIV 
virus reached its peak titer at a faster rate than the WT/WT virus (Fig. 17).  



















Figure 15. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 37oC in MDCK 
Cells. A multistep growth curve was performed on MDCK cells with the indicated viruses. 
Statistical differences were determined by MANOVA followed by Bonferroni post-test. *=P < 



























32C - LAIV/WT vs LAIV/LAIV
LAIV/WT
LAIV/LAIV ns
Figure 16. Effect of NS Gene Swap in the LAIV backbone at 32oC in A549 Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 




 2.3.5 Replication of NS Reassortant Viruses at 37oC in A549 Cells 
 
Multistep growth curves were also performed at 37oC to evaluate any temperature 
sensitive phenotypes in the virus panel. The A549 cells were inoculated at an MOI = 0.55.  
Similar to what was observed at 32oC, the LAIV/LAIV and LAIV/WT viruses 
demonstrated no significant differences in replication kinetics at 37oC (Fig. 18). They both 
reached roughly the same peak titer in the same amount of time. For the WT viruses, 
however, the WT/LAIV virus reached its peak titer faster than the WT/WT virus. Both 
viruses achieved roughly the same peak titer (Fig. 19). 
 


















Figure 17. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 32oC in A549 Cells. 
A multistep growth curve was performed on MDCK cells with the indicated viruses. Statistical 
differences were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 























Figure 18. Effect of NS Gene Swap in the LAIV backbone at 37oC in A549 Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 





 Previous work suggests that mutations which arise in the NS gene during the serial 
passage process of LAIV may contribute to viral attenuation and/or temperature sensitivity 
66. We examined this through NS gene segment reassortments in a panel of viruses. 
Although this does not allow us to determine the specific mutations that may contribute to 
an attenuation phenotype, we would be able to determine what role, if any, the entire gene 
segment has in viral replication. To test this, we performed several multistep growth curves 
between the NS reassortant viruses outlined in Table 3.  
In MDCK cells at a low MOI (MOI = 0.01), there were significant differences 
between LAIV/LAIV and LAIV/WT, as well as significant differences between WT/LAIV 
and WT/WT. In both backbones, the virus with the LAIV NS gene segment had faster 
Figure 19. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 37oC in A549 Cells. 
A multistep growth curve was performed on MDCK cells with the indicated viruses. Statistical 
differences were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 
0.01; ***=P<0.001. L.O.D=limit of detection=2.37. 



















replication kinetics than its wild-type matched NS counterpart. However, all viruses 
eventually reached roughly the same peak titer. This trend was observed at both 32oC and 
37oC, which indicates that the NS gene is not responsible for the temperature sensitive 
phenotype in cell culture. 
We also conducted multistep growth curves at a high MOI (MOI = 0.55) in A549 
cells, which represents a more humanized model of infection (compared to canine kidney 
cells). In the A549 cell culture system, the LAIV-backbone viruses were found to have no 
significant differences in growth kinetics or peak titer from one another at 32oC or 37oC. In 
the WT backbone, the WT/LAIV had significantly faster growth at both 32oC and 37oC. At 
32oC, the WT/LAIV virus had a higher peak titer (~100 fold greater) than WT/WT. For the 
WT viruses, these data indicate the NS gene has a role in viral replication. However, in 
the context of these data, we are unable to determine which of the two proteins encoded 
by the NS gene, NS1 or NEP, are contributing to this phenotype. NEP is likely to be the 
larger contributor because it associates with the M2 protein during viral assembly, 
whereas NS1 primarily antagonizes the innate immune response. 
 
Chapter 3 - Recombinant influenza expressing mutations 
at amino acid 153 that are associated with the cold 




 3.1.1 Interest in aa 153 
 
 The genome of LAIV has developed a series of mutations which allow it to survive 
and propagate at 25oC in embryonated hen’s eggs. I wanted to take a deeper look into 
 44 
how these mutations influence viral growth and replication. Of particular interest is the aa 
153 mutation in the NS1 protein. I want to generate a panel of NS1 aa 153 mutant viruses 
in both the LAIV and circulating wt A/Victoria/361/2011 backbones. This will allow us to 
determine if the aa 153 mutation first observed by Cox et al. has any influence on the 
attenuation of LAIV. 
 
 3.1.2 Virus Mutant Selection 
 
 When observing the relative amino acid frequency of current H3N2 human clinical 
isolates, glutamic acid is by far the most prevalent genotype, accounting for roughly 99% 
of collected samples. 
 For our mutations in the A/Victoria/361/2011 backbone, E153 will serve as the 
baseline genotype. However, when we use the same search parameters for avian species, 
aspartic acid is the most prevalent phenotype, accounting for roughly three-quarters of 
isolates. - glutamic acid accounts for the remaining one-quarter of isolates. Although the 
side chains are very similar in structure and property, it would also be interesting to see 
what effect a D153 mutation has on virus phenotype. 
 LAIV exhibits a T153 genotype - this will serve as the baseline amino acid for all 
work conducted in the LAIV backbone. When compared to the original wt A/Ann 
Arbor/6/60 clinical isolate, a A153 genotype is observed. I wanted to create mutations in 
the LAIV backbone that reflect a reversion to the A153 genotype, a conversion to the wt 
H3N2 E153 genotype, and a conversion to the avian D153 genotype. Furthermore, we will 
create similar mutations in the A/Victoria/361/2011 backbone that reflect conversions to 
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the wt A/Ann Arbor/6/60 A153 genotype, LAIV’s T153 genotype, and the avian D153 
genotype. These viruses are listed in Tables 4 and 5. 
 
 
Table 4. Panel of aa 153 Viruses in A/Victoria/361/2011 Backbone 




3.2 Materials and Methods 
 
 3.2.1 Cell Lines 
 
 Madin Darby canine kidney (MDCK) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
ug/mL streptomycin and 2mM L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 
dilution every 3-4 days. 
 Transformed human embryonic kidney 293 cells (293T) were maintained in DMEM 
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 ug/mL streptomycin and 2mM 
L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 dilution every 3-4 days. 
 
 3.2.2 Plasmids 
 
Table 6. Frequency of Amino Acids Isolated from North American Clinical Samples (aa 153) 
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 The pHH21 plasmid for the NS segment encodes the influenza 
A/Victoria/361/2011 and LAIV NS segment under the control of human RNA polymerase 
I promoter and murine RNA polymerase I terminator. This pHH21 plasmid encoding the 
NS segment was mutated using the the Quickchange Site-Directed Mutagenesis Kit 
(Stratagene) to induce mutations at aa 153. Forward and reverse primers were designed 
to create desired mutations and their sequences are shown in Table 7 (Integrated DNA 
Technologies). The pHH21 plasmid and the primers of interest were subjected to PCR. 
Dpn1 enzyme was used to cleave and remove supercoiled parental plasmid from the PCR 
mixtures. The purified PCR mixture was transformed into competent bacterial (Ultra Gold) 
cells. Several bacterial colonies were selected for each mutant and their DNA purified 
using the QIAprep Spin Miniprep Kit (Qiagen). The DNA was sequenced using the FluA5 
















 3.2.3 Recombinant Viruses 
 
 A 12 plasmid recombinant virus rescue system was utilized to generate the panel 
viruses (Neumann et al., 1999). 6-well plates were coated with poly-L-lysine and 293T 
cells were plated at 40-60% confluence 24 hours prior to transfection. For the 
A/Victoria/361/2011 viruses, 293T cells were transfected with A/Victoria/361/2011 pHH21 
plasmids encoding PB2, PB1, PA, NP, NA, HA, M (0.5 μg each) and NS (1.0 μg). For the 
Plasmid Forward Primer Reverse Primer 
pHH21 A/Vic-NS1-E153A 5’ CCA ACA ATT GCT CCG 
GCT TCG GTG AAA GCC 
CTT AGT AAT ACT AT 3’ 
5’ ATA GTA TTA CTA AGG 
GCT TTC ACC GAA GCC 
GGA GCA ATT GTT GG 3’ 
pHH21 A/Vic-NS1-E153D 5’ CCA ACA ATT GCT CCG 
TCT TCG GTG AAA GCC 
CTT AGT AAT ACT AT 3’ 
5’ ATA GTA TTA CTA AGG 
GCT TTC ACC GAA GAC 
GGA GCA ATT GTT GG 3’ 
pHH21 A/Vic-NS1-E153T 5’ CCA ACA ATT GCT CCC 
GTT TCG GTG AAA GCC 
CTT AGT AAT ACT AT 3’ 
5’ ATA GTA TTA CTA AGG 
GCT TTC ACC GAA ACG 
GGA GCA ATT GTT GG 3’ 
pHH21 LAIV-NS1-T153A 5’ CCA ACA ATT GCT CCG 
GCT TCG GTG AAA GCC 
CTT AGT AAT AAT AT 3’ 
5’ CTA ATA TTA CTA AGG 
GCT TTC ACC GAA GCC 
GGA GCA ATT GTT GG 3’ 
pHH21 LAIV-NS1-T153D 5’ CCA ACA ATT GCT CCG 
TCT TCG GTG AAA GCC 
CTT AGT AAT ATT AT 3’ 
5’ CTA ATA TTA CTA AGG 
GCT TTC ACC GAA GAC 
GGA GCA ATT GTT GG 3’ 
pHH21 LAIV-NS1-T153E 5’ CCA ACA ATT GCT CCC 
TCT TCG GTG AAA GCC 
CTT AGT AAT ATT AT 3’ 
5’ CTA ATA TTA CTA AGG 
GCT TTC ACC GAA GAG 
GGA GCA ATT GTT GG 3’ 
Table 7. Sequences of Primers used to Generate Recombinant Viruses at aa 153
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with the LAIV genome, 293T cells were transfected with LAIV pHH21 plasmids encoding 
PB2, PB1, PA, NP, NA, HA, M (0.5 μg each) and NS (1.0 μg). All viruses were transfected 
with helper plasmids under the control of RNA polymerase II promoters encoding 
A/Udorn/72 PB1, PB2, NP (1μg each) and PA (0.2 μg).  
 Transfection reagent TransIT-LT-1 (LT1) (Mirus) (20 μL/transfection) was mixed 
with OptiMEM medium (Gibco) (100 μL/transfection) and incubated at room temperature 
for 15 minutes. Plasmids were mixed at the aforementioned quantities, added to the 
LT1/OptiMEM mixture, and incubated at room temperature for another 15 minutes. DMEM 
was aspirated from 6-well plates containing 293T cells and replaced with 2 mL/well of 
OptiMEM. The corresponding transfection mix was added dropwise to each well. The 
plates were incubated at 32oC with 5% CO2. 24 hours following transfection, 2.24 μL of 5 
μg/mL N-acetyl trypsin (NAT) (Sigma) was added to each well to bring the total 
concentration of NAT to 10 μg/mL. The cells were incubated at 32oC with 5% CO2 for 4 
hours and then each well overlaid with approx. 5*105 MDCK cells suspended in 100 μL 
OptiMEM. The plates were transferred to a 37oC incubator. Every 24 hours for approx. 
five days, 1 mL of supernatant was removed from the cells and replaced with 1 mL DMEM 
with 4 μg/mL NAT, 100 U/mL penicillin, 100 μg/mL streptomycin, 2mM L-glutamine, and 
0.5% bovine serum albumin (BSA) (Sigma) (IM+NAT). Transfection was discontinued 
when indications of comprehensive cytopathic effects were observed. 
 
 3.2.4 TCID50 Assay 
 
 Fifty percent tissue culture infectious dose (TCID50) were utilized to determine viral 
titers. MDCK cells were plated to confluence in 96-well plates. Viral supernatants were 
diluted at concentrations from 10-1 to 10-8 in IM+NAT. 20 μL of each 10-fold dilution was 
 50 
added to six consecutive wells on a confluent 96-well plate containing MDCK cells. These 
plates were incubated at 32oC with 5% CO2 for 7 days. The cells were fixed with 4% 
formaldehyde and stained with naphthol blue-black overnight. Cytopathic effects (CPE) 
were scored visually and TCID50 was quantified using the Reed and Muench calculation. 
 
 3.2.5 Plaque Purification 
 
 Recombinant influenza viruses generated following transfection must be purified 
from the transfection supernatant. 6-well plates were seeded with MDCK cells and seeded 
to confluence. 100 μL of transfection supernatant was serially diluted ten-fold from 10-1 to 
10-8 with IM+NAT. 6-well plates were aspirated and washed twice with PBS+. 250 μL of 
diluted virus (dilutions determined from TCID50 of transfection supernatant) was added to 
each well. The 6-well plates were incubated for one hour at 32oC for viruses with LAIV 
polymerase genes and 37oC for viruses with A/Victoria/361/2011 polymerase genes. 
During the incubation period, the plates were gently tapped every 15 minutes to evenly 
distribute virus. Following incubation, the inoculum was aspirated and replaced with ~ 4 
mL of a mixture of 2% agarose, 2X Modified Eagle’s Medium (MEM), and 4 μg/mL NAT. 
Plates were incubated at 32oC for 72-120 hours. Clear, defined, and singular plaques were 
picked using a 1 mL serological pipette, placed into tubes containing 500 μL IM, and stored 
at -80oC. 
 
 3.2.6 Virus Infection to Generate Viral Stocks 
 
 MDCK cells were grown to confluence in T150 (150 cm2) flasks. 100 μL of the 
media from the plaque resuspension was added to 5 mL IM+NAT. The media was 
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aspirated from the T150 flasks and replaced by the virus and IM mixture. The flasks were 
incubated for one hour at 32oC for viruses with LAIV polymerase genes and 37oC for 
viruses with A/Victoria/361/2011 polymerase genes. During the incubation period, the 
plates were gently tapped every 15 minutes to evenly distribute virus. Following the one 
hour incubation, the inoculum was aspirated and replaced with 20 mL IM. The cells were 
monitored daily for CPE and the supernatants harvested after 30-40% of cells were dead 
or had detached from the flask. 200 μL of supernatant was harvested and used to establish 
a bank of viral seed stocks. The seed stocks were sequenced to confirm a purified virus 
product and later titered via TCID50 assay. Once viral sequencing was completed, working 
stocks were generated from the seed stocks (MOI = 0.001) in the manner described 




3.3.1 Rescue of Recombinant Influenza Viruses Encoding NS1 aa 153 Mutations 
 
 Viruses encoding a mutation at aa 153 in both the A/Victoria/361/2011 and LAIV 
backbone were successfully rescued. The NS gene was sequenced to confirm presence 
of desired aa 153 mutation. The seven remaining gene segments were sequenced to 




 Unfortunately, due to time constraints, the viral growth kinetics of the aa 153 
viruses could not be evaluated. However, a panel of these viruses in both the LAIV and 
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A/Victoria/361/2011 backbones were generated, sequenced, and aliquoted into seed 
stocks for a future thesis project. 
 
Chapter 4 – Conclusion and Future Directions 
 
 Previous research conducted in our lab demonstrated that in human nasal 
epithelial cells at 32oC, wild-type A/Victoria/361/2011 reached higher peak titers at a faster 
rate than LAIV. For my NS reassortant viruses, I would have anticipated this trend to 
remain the same, and those reassortants with the wild-type NS to have faster growth 
kinetics than the lineage-matched reassortant with LAIV NS. However, the opposite trend 
was observed and those reassortants with LAIV NS had faster growth kinetics than the 
reassortants with wild-type NS. These data indicate the NS gene may play a role in 
influenza replication.  
Since LAIV is developed in embryonated hen’s eggs, we believe we can apply this 
project to an avian model. We could study NS gene reassortment in embryonated hen’s 
eggs or primary chick fibroblasts and compare that to our data in A549 cells. Ideally, we 
would like to conduct research in a more humanized model like human nasal epithelial 
cells and/or human tracheal cells and compare that to avian cells. Based off the data 
presented in this project, I’d expect the reassortant viruses with LAIV NS to have faster 
growth kinetics than the viruses with wild-type NS in a human model. I would expect the 
same in an avian model. LAIV has adapted to replicate efficiently within embryonated 
hen’s eggs whereas wild-type viruses have adapted to growth within epithelial cells. In an 
avian model, viruses with LAIV NS would likely have a replication advantage.  
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The data presented in this project primarily investigated the role of the NS gene in 
viral replication, however we know one of its encoded proteins, NS1, is an immune system 
antagonist. We believe the NS reassortment viruses should also be evaluated for their 
innate immune inhibition. Reporter gene assays will allow us to measure the induction of 
cellular signaling pathways including NF-KB, JAK/STAT, and MAPK. We can also take a 
more in depth look at innate immune responses by specifically measuring known viral 
response factors including IRF3/7 phosphorylation and Type I and III interferon induction. 
Furthermore, we’d like to analyze the chemokines and cytokines that are secreted in 
human nasal epithelial cells in response to influenza infection. When taken from harvested 
supernatants from a growth curve, we can look at what/when chemokines and cytokines 
are excreted after being infected with influenza. Furthermore, since these cells are 
polarized, we can compare the apical and basolateral media to see if there are any 
differences in secretion. Analyzing the supernatants for specific chemokines and cytokines 
will provide insight into what innate immune cells may be recruited to combat influenza 
infection. 
Although time constraints prevented characterization of the aa 153 recombinant 
viruses, we can still hypothesize how they might replicate in humanized cells. For the wild-
type viruses, I’d expect E153A to have the fastest growth kinetics, as this is the amino 
acid found at residue 153 in the A/Ann Arbor/6/60 wild-type virus. The other mutation, 
E153T, represents the LAIV sequence. Since other point mutations within the LAIV 
genome have been connected to attenuation and temperature-sensitive phenotypes, we 
believe the same would be true for our viruses, and predict that E153T would likely confer 
a degree of attenuation. For the LAIV viruses, there is less experimental evidence to 
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predict how these mutations would affect their growth. 153A is the WT A/Ann Arbor/6/60 
sequences and 153E is found in currently circulating H3N2 viruses.  
We believe this work can be applied to the development of an adapted LAIV 
vaccine strain. Based on the data in this project, it’s important to keep the LAIV polymerase 
genes as the core of the virus – this confers a temperature sensitive phenotype that inhibits 
the virus from replicating at 37oC. However, our data indicates that a wild-type NS gene 
should be swapped with the LAIV NS. Our LAIV NS reassortant viruses had faster growth 
rates and even significantly higher titers than the viruses with wild-type NS. For a LAIV 
vaccine strain, we want a virus that is both temperature sensitive and attenuated – a virus 
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Unfortunately for epidemiologists and public health professionals, there is no 
discrete, singular reason why influenza infections peak during the winter months. One 
theory posits that serum levels of Vitamin D drop during this time as people are less likely 
to be outside27. Vitamin D has been connected to promoting mucosal and CD4+ T cell 
responses, so influenza may be able to infect hosts more readily as Vitamin D levels drop 
28. Some believe the seasonality of flu is related to social and behavioral factors including 
crowding which helps transmission by exposing more people to the aerosolized droplets 
of an infected individual 29. A new theory suggests that the innate immune response is 
dampened by a drop in ambient temperature. Foxman et al. demonstrated that rhinovirus 
is able to infect humans more readily at 33o C due to diminished response by Type I 
interferons 30. It would be particularly interesting to see if lowered ambient temperatures 
Figure 2. Positive Influenza Infection Tests in the Southern Hemisphere during 2016-2017. 
WHO, 2017 
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In European countries, finalized vaccine candidates must undergo clinical studies to prove 
their safety and immunogenicity - this is not required in the United States. 
 1.3.2 Vaccine Composition 
 
 There are two formulations for the annual vaccine. The most common is the 
injectable formulation that contains formalin-inactivated virions34. These virions have no 
ability to replicate within the host, but are capable of inducing a memory response by the 
immune system. The inactivated vaccine has greatest efficacy in patients above the age 
of 6 35. The increased efficacy in older children is most likely attributable to past infection 
with influenza virus.  
 The other formulation is a live attenuated influenza vaccine (LAIV) that is 
administered through a nasal spray into the nasopharyngeal region of the upper 
respiratory tract36. As the name implies, this is a live virus that can replicate within the 
host, but does not cause disease. This area of the body maintains a temperature around 
32oC which permits localized viral growth, but prevents systemic infection into the lower 
airways which maintain a temperature around 37oC. LAIV is of note because its 
administration has been connected to a broad and systemic IgA mucosal response to not 
Figure 3. Flu Vaccine Development Timeline for the Northern Hemisphere. USA Today, 2009 
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also known as the RNA-binding domain, and then the C-terminal domain, also known as 
the effector domain 43.  
 
 1.4.2 Structure and Function of the N-terminal Domain 
 
 The N-terminal domain is roughly defined as amino acids 1-73 of the NS1 protein. 
As mentioned previously, the N-terminal domain of NS1 is responsible for directly binding 
host RNA and preventing its transcription into proteins. The N-terminal domain forms a 
homodimer in solution that consists of three "-helical domains which constitute the 
majority of secondary structure for this region of the protein. This dimerization is crucial 
for RNA binding. The "-helices of the homodimer form a unique chain fold that binds RNA 
between the 2 and 2’ chains 43. Research has determined that within the second "-helix, 
R38 and K41 are the two crucial amino acids needed for RNA-binding 44 
 The NS1 N-terminal domain is well-known for inhibiting the 2’-5’ oligoadenylate 
synthetase (OAS)/RNAse L pathway. The OAS/RNAse L pathway is activated by IL-1#, a 











1.5.3 NS1 Mutations in LAIV 
 
 It’s clear that point mutations are responsible for the attenuation and temperature 
restriction of LAIV. Most of the mutations occur in the genes encoding viral polymerases, 
however a few have been discovered elsewhere in the genome, notably in the NS gene.  
 Work conducted by Cox et al. mapped one mutation in the coding region of the NS 
gene segment. Occurring at amino acid 153, the mutation from an alanine (wt) to a 
threonine (LAIV) was the only difference in the coding region of the NS gene of cold 
adapted A/Ann Arbor/6/60 when compared to the wt 66. When examined in the same 
context as some of the other gene segments, it’s reasonable to infer that the mutation at 
aa 153 of NS might have a role in LAIV attenuation.  
Figure 5. Formulation of LAIV. Modified from NIAID. 
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1.5.4 Previous Data 
 
 Work conducted by Fenstermacher and Forero examined the growth kinetics of 
HA/NA-antigenically matched LAIV and wt A/Victoria/361/2011 in cultures of human nasal 
epithelial cells (hNECs) at 33oC. They found that over a seven day period, infectious 
particle production as well as growth rate in LAIV was less than its wt counterpart 67.  
 In addition to altered growth kinetics, LAIV differentially induces the host innate 
immune response when compared to a wt virus. When hNEC cells were infected at a high 







Segment Coding Changes Mutation Effect 
PB2 1 N265S Attenuation, Temp. Sensitivity 
PB1 4 K391E, E457D, E581G, A661T Attenuation, Temp. Sensitivity 
PA 2 K613E, L715P Cold Adaptation, Attenuation 
NP 2 T23N, A34G ? 
M 1 A86S Attenuation 
NS 1 A153T ? 





















At 24 hours post infection, LAIV induces over twice the amount of unique genes 
when compared to the wt. Furthermore, at 36 hours post infection, LAIV induces six times 
Figure 7. LAIV Differentially Induces the Immune Response. Forero and Fenstermacher et al., 
ahead of print. 
Figure 6. LAIV Demonstrates Altered Growth Kinetics when Compared to wt 
A/Victoria/361/2011. Forero and Fenstermacher et al., ahead of print. 
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of both its parental viruses which can have a profound impact on virulence within a naive 
host.  
 This process of reassortment is commonly known as genetic shift when it involves 
the HA gene segment and is a hallmark of influenza diversity and adaptation. Many 
pandemic strains have formed as a result of gene reassortment including the 1918 H1N1, 
1957 H2N2, 1968 H3N2, and most recently 2009 H1N1 outbreak. A closer look at the 
1918 pandemic strain shows the acquisition of an avian HA gene which drastically 













2.1.2 Reassortant Viruses in the Laboratory 
 
 In the laboratory, we are able to manually induce gene reassortment to create new 
influenza viruses. In fact, this is done on an annual basis with LAIV which contains the six 
internal cold adapted genes from the attenuated virus, as well as the two external genes 
Figure 8. Hypothetical Reassortment of Influenza within a Swine Host. Stevens et al., 2006. 
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from the circulating virus subtypes. When a single segment is substituted for another, the 
resulting virus is referred to as a “7:1 virus” to represent the seven original segments and 
the one transplant segment. These reassortant viruses are useful in determining the 
influence of a particular segment on viral phenotype. For example, the aforementioned 
work conducted by Pappas et al. was done with reassorted H1N1 viruses to elucidate that 
HA was the crucial segment conferring enhanced virulence in the 1918 pandemic strain. 
For the purposes of this project, we intend to do NS gene swaps between LAIV and wt 
A/Victoria/361/2011.  
 
 Lineage of Segments 1-7 Lineage of NS Segment Abbreviation 
1 A/Victoria/361/2011 A/Victoria/361/2011 WT/WT 
2 A/Victoria/361/2011 LAIV WT/LAIV 
3 LAIV LAIV LAIV/LAIV 
4 LAIV A/Victoria/361/2011 LAIV/WT 
 
Table 3. 7:1 Virus Panel 
Figure 9. Representation of 7:1 NS Gene Swaps between wt A/Victoria/361/2011 and LAIV 
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Since the NS segment encodes two proteins, NS1 and NEP, sequence alignments 
of wild type A/Victoria/361/2011 and LAIV NS1 and NEP were performed in order to 
examine amino acid differences. There are 28 discrete amino acid differences between 
the wild type and LAIV NS1 proteins. In regards to NEP, there are 7 discrete amino acid 
differences.  When used in our NS reassortant virus system, this variation in amino acids 
between the protein sequences might shed light on LAIV attenuation. 
 
2.2 Materials and Methods 
 
 2.2.1 Cell Lines 
 
 Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
ug/mL streptomycin and 2mM L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 
dilution every 3-4 days. 
Figure 10. Sequence Alignment of wild type A/Victoria/361/2011 and LAIV NS1 
Figure 11. Sequence Alignment of wild type A/Victoria/361/2011 and LAIV NEP 
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the WT/WT virus, however both reached roughly the same peak titer at 72 hours post 
infection (Fig. 13). 
 
 



















Figure 12. Effect of NS Gene Swap in the LAIV backbone at 32oC in MDCK Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 





2.3.3 Replication of NS Reassortant Viruses at 37oC in MDCK Cells 
 
 A multistep growth curve was also performed at 37oC to mimic an infection of the 
lower respiratory tract, which is also representative of core body temperature. Once again, 
the LAIV/LAIV virus had significantly faster replication kinetics than LAIV/WT, but both 
viruses achieved roughly the same peak titer at 48 hours post infection (Fig. 14). 
Additionally, the WT/LAIV virus had significantly faster replication kinetics than the WT/WT 
virus, however both strains reached roughly the same peak titer at 48 hours post infection 
(Fig. 15). 



















Figure 13. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 32oC in MDCK 
Cells. A multistep growth curve was performed on MDCK cells with the indicated viruses. 
Statistical differences were determined by MANOVA followed by Bonferroni post-test. *=P < 



































Figure 14. Effect of NS Gene Swap in the LAIV backbone at 37oC in MDCK Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 
***=P<0.001. L.O.D=limit of detection=2.37. 
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2.3.4 Replication of NS Reassortant Viruses at 32oC in A549 Cells 
 
 A549 cells were infected to further evaluate viral growth kinetics for the NS 
reassortant viruses. Originating from adenocarcinomic alveolar basal epithelial cells, 
A549s present a more humanized model for influenza infection than MDCK cells. The 
A549 cells were infected at an MOI = 0.55. 
 A multistep growth curve was performed at 32oC. For the viruses in the LAIV 
backbone, the LAIV/LAIV and LAIV/WT viruses show no significant difference in 
replication kinetics " both viruses reached roughly the same peak titer at a similar rate 
(Fig. 16). For the viruses in the A/Victoria/361/2011 backbone, the WT/LAIV virus reached 
a peak titer nearly 100-fold greater than its WT/WT counterpart. Furthermore, the WT/LAIV 
virus reached its peak titer at a faster rate than the WT/WT virus (Fig. 17).  



















Figure 15. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 37oC in MDCK 
Cells. A multistep growth curve was performed on MDCK cells with the indicated viruses. 
Statistical differences were determined by MANOVA followed by Bonferroni post-test. *=P < 



























32C - LAIV/WT vs LAIV/LAIV
LAIV/WT
LAIV/LAIV ns
Figure 16. Effect of NS Gene Swap in the LAIV backbone at 32oC in A549 Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 




 2.3.5 Replication of NS Reassortant Viruses at 37oC in A549 Cells 
 
Multistep growth curves were also performed at 37oC to evaluate any temperature 
sensitive phenotypes in the virus panel. The A549 cells were inoculated at an MOI = 0.55.  
Similar to what was observed at 32oC, the LAIV/LAIV and LAIV/WT viruses 
demonstrated no significant differences in replication kinetics at 37oC (Fig. 18). They both 
reached roughly the same peak titer in the same amount of time. For the WT viruses, 
however, the WT/LAIV virus reached its peak titer faster than the WT/WT virus. Both 
viruses achieved roughly the same peak titer (Fig. 19). 
 


















Figure 17. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 32oC in A549 Cells. 
A multistep growth curve was performed on MDCK cells with the indicated viruses. Statistical 
differences were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 























Figure 18. Effect of NS Gene Swap in the LAIV backbone at 37oC in A549 Cells. A multistep 
growth curve was performed on MDCK cells with the indicated viruses. Statistical differences 
were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 0.01; 





 Previous work suggests that mutations which arise in the NS gene during the serial 
passage process of LAIV may contribute to viral attenuation and/or temperature sensitivity 
66. We examined this through NS gene segment reassortments in a panel of viruses. 
Although this does not allow us to determine the specific mutations that may contribute to 
an attenuation phenotype, we would be able to determine what role, if any, the entire gene 
segment has in viral replication. To test this, we performed several multistep growth curves 
between the NS reassortant viruses outlined in Table 3.  
In MDCK cells at a low MOI (MOI = 0.01), there were significant differences 
between LAIV/LAIV and LAIV/WT, as well as significant differences between WT/LAIV 
and WT/WT. In both backbones, the virus with the LAIV NS gene segment had faster 
Figure 19. Effect of NS Gene Swap in the A/Victoria/361/2011 backbone at 37oC in A549 Cells. 
A multistep growth curve was performed on MDCK cells with the indicated viruses. Statistical 
differences were determined by MANOVA followed by Bonferroni post-test. *=P < 0.05; **= P < 
0.01; ***=P<0.001. L.O.D=limit of detection=2.37. 



















the wt A/Ann Arbor/6/60 A153 genotype, LAIV’s T153 genotype, and the avian D153 
genotype. These viruses are listed in Tables 4 and 5. 
 
 
Table 4. Panel of aa 153 Viruses in A/Victoria/361/2011 Backbone 




3.2 Materials and Methods 
 
 3.2.1 Cell Lines 
 
 Madin Darby canine kidney (MDCK) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
ug/mL streptomycin and 2mM L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 
dilution every 3-4 days. 
 Transformed human embryonic kidney 293 cells (293T) were maintained in DMEM 
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 ug/mL streptomycin and 2mM 
L-glutamine at 37oC with 5% CO2 and passaged at a 1:10 dilution every 3-4 days. 
 
 3.2.2 Plasmids 
 




 3.2.3 Recombinant Viruses 
 
 A 12 plasmid recombinant virus rescue system was utilized to generate the panel 
viruses (Neumann et al., 1999). 6-well plates were coated with poly-L-lysine and 293T 
cells were plated at 40-60% confluence 24 hours prior to transfection. For the 
A/Victoria/361/2011 viruses, 293T cells were transfected with A/Victoria/361/2011 pHH21 
plasmids encoding PB2, PB1, PA, NP, NA, HA, M (0.5 $g each) and NS (1.0 $g). For the 
Plasmid Forward Primer Reverse Primer 
pHH21 A/Vic-NS1-E153A 5! CCA ACA ATT GCT CCG 
GCT TCG GTG AAA GCC 
CTT AGT AAT ACT AT 3! 
5! ATA GTA TTA CTA AGG 
GCT TTC ACC GAA GCC 
GGA GCA ATT GTT GG 3! 
pHH21 A/Vic-NS1-E153D 5! CCA ACA ATT GCT CCG 
TCT TCG GTG AAA GCC 
CTT AGT AAT ACT AT 3! 
5! ATA GTA TTA CTA AGG 
GCT TTC ACC GAA GAC 
GGA GCA ATT GTT GG 3! 
pHH21 A/Vic-NS1-E153T 5! CCA ACA ATT GCT CCC 
GTT TCG GTG AAA GCC 
CTT AGT AAT ACT AT 3! 
5! ATA GTA TTA CTA AGG 
GCT TTC ACC GAA ACG 
GGA GCA ATT GTT GG 3! 
pHH21 LAIV-NS1-T153A 5! CCA ACA ATT GCT CCG 
GCT TCG GTG AAA GCC 
CTT AGT AAT AAT AT 3! 
5! CTA ATA TTA CTA AGG 
GCT TTC ACC GAA GCC 
GGA GCA ATT GTT GG 3! 
pHH21 LAIV-NS1-T153D 5! CCA ACA ATT GCT CCG 
TCT TCG GTG AAA GCC 
CTT AGT AAT ATT AT 3! 
5! CTA ATA TTA CTA AGG 
GCT TTC ACC GAA GAC 
GGA GCA ATT GTT GG 3! 
pHH21 LAIV-NS1-T153E 5! CCA ACA ATT GCT CCC 
TCT TCG GTG AAA GCC 
CTT AGT AAT ATT AT 3! 
5! CTA ATA TTA CTA AGG 
GCT TTC ACC GAA GAG 
GGA GCA ATT GTT GG 3! 
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